GSK is finally settling Zantac litigation with manageable terms, removing a major overhang. Arexvy RSV vaccine is being squeezed by Pfizer and Moderna competition in the same season. HIV franchise (Tivicay, Dovato) faces increasing GLP-1 prescriber competition for primary care attention. Shingrix remains a steady performer. Pipeline lacks a clear blockbuster catalyst.
Thesis reviewed May 29, 2026
GSK plc is headquartered in United Kingdom, which is currently showing moderate signals.
🇬🇧United Kingdom52NEUTRALView United Kingdom risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 50 | +11% | ↓0% | EARLY |
| JNJ | Johnson & Johnson | 50 | +8% | ↓0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | ↓0% | AVOID |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | ↓0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| PFE | Pfizer Inc. | 50 | +6% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
Investors who hold GSK may also have indirect exposure through these country funds.
GSK reaches $2.2B Zantac global settlement framework
Arexvy season-2 uptake softer than Pfizer Abrysvo
HIV pipeline candidate misses on Phase 2 durability
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Marjorie Taylor Mrs GreeneGA | R | Buy | $1k–$15k | Nov 25, 24 | +56.2% |
| Marjorie Taylor Mrs GreeneGA | R | Buy | $1k–$15k | Sep 3, 24 | +22.5% |